Drug Trial Radar · NCT06810544
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
191
Planned (sponsor's estimate)
Start
Mar 24, 2025
Primary completion
Mar 31, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Tango Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Conditions
- Non Small Cell Lung Cancer
- Glioma Glioblastoma Multiforme
- Glioma, Malignant
- Solid Tumor
- Non-Small Cell Adenocarcinoma
- Lung Cancer
- Brain Tumor
Interventions
TNG456Drug
A selective PRMT5 inhibitor
abemaciclibDrug
A kinase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Maximum Tolerated DoseTime frame: 21 days
- Phase 2 Anti-neoplastic Activity Single AgentTime frame: 18 weeks
- Phase 2 Anti-neoplastic Activity Combination TreatmentTime frame: 18 weeks
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona · Recruiting
University of California, Irvine
Irvine, California · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
University of California at San Francisco
San Francisco, California · Recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota · Recruiting
NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.